AgomAb Therapeutics NV SEC filings AGMB
AgomAb Therapeutics NV has 49 filings in SEC EDGAR's recent list, going back to Jun 20, 2024. Its latest annual report, Form 20-F, was filed on Apr 23, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Oct 13, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 4 | Insider transaction | Nov 6, 2026 | Nov 5, 2026 |
| 4 | Insider transaction | Oct 22, 2026 | Oct 21, 2026 |
| 6-K | Current report (foreign issuer) | Oct 13, 2026 | Oct 13, 2026 |
| 4 | Insider transaction | Oct 9, 2026 | Oct 8, 2026 |
| 4 | Insider transaction | Oct 7, 2026 | Oct 5, 2026 |
| 4 | Insider transaction | Oct 7, 2026 | Oct 6, 2026 |
| 4 | Insider transaction | Oct 7, 2026 | Oct 5, 2026 |
| 6-K | Current report (foreign issuer) | Oct 1, 2026 | Oct 1, 2026 |
| 4 | Insider transaction | Sep 15, 2026 | Sep 11, 2026 |
| 4 | Insider transaction | Sep 15, 2026 | Sep 11, 2026 |
| 3 | Initial insider ownership | Sep 15, 2026 | Sep 11, 2026 |
| 3 | Initial insider ownership | Sep 15, 2026 | Sep 11, 2026 |
| 6-K | Current report (foreign issuer) | Sep 14, 2026 | Sep 14, 2026 |
| 6-K | Current report (foreign issuer) | Sep 11, 2026 | Sep 11, 2026 |
| 6-K | Current report (foreign issuer) | Aug 10, 2026 | Aug 10, 2026 |
| 6-K | Current report (foreign issuer) | Aug 6, 2026 | Aug 6, 2026 |
| 6-K | Current report (foreign issuer) | Jun 23, 2026 | Jun 23, 2026 |
| 6-K | Current report (foreign issuer) | May 27, 2026 | May 27, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | May 15, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | May 15, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | May 6, 2026 | — |
| 6-K | Current report (foreign issuer) | Apr 24, 2026 | Apr 24, 2026 |
| 20-F | Annual report (foreign issuer) | Apr 23, 2026 | Dec 31, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | Apr 16, 2026 | — |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| S-8 | Employee stock plan registration | Mar 11, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Mar 6, 2026 | — |
| 6-K | Current report (foreign issuer) | Mar 5, 2026 | Mar 5, 2026 |
| SCHEDULE 13D | Ownership over 5% (active) | Feb 17, 2026 | — |
| 6-K | Current report (foreign issuer) | Feb 9, 2026 | Feb 9, 2026 |
| 424B4 | Prospectus | Feb 6, 2026 | — |
| CERT | Filing | Feb 5, 2026 | — |
| 8-A12B | Form 8-a12b | Feb 3, 2026 | — |
| EFFECT | Filing | Jan 30, 2026 | — |
| F-1/A | Filing | Jan 29, 2026 | — |
| F-1 | Registration statement (foreign issuer) | Jan 16, 2026 | — |
| DRS/A | Filing | Dec 17, 2025 | — |
| DRS/A | Filing | Oct 28, 2025 | — |
| DRS | Filing | Jun 20, 2024 | — |
Showing 49 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- AGMB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Belgium
- Headquarters
- Antwerpen
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 2020932
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.